Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 6/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185869 | 0.87 | MAPT (1.00) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL6760865 | 0.86 | MEN1 (0.77) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL5245834 | 0.86 | MEN1 (0.77) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL5245777 | 0.86 | MEN1 (0.77) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL570779 | 0.84 | PIK3CD (0.67) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL5287286 | 0.83 | MEN1 (0.71) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL6764058 | 0.83 | MEN1 (0.71) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL8153875 | 0.83 | MAPT (0.71) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL5242768 | 0.82 | KDM4E (0.78) | KMT2AMAPTMEN1KDM4EPKM | |
| SCHEMBL5246622 | 0.80 | MEN1 (0.67) | KMT2AMAPTMEN1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | claimed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | claimed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | claimed |
| EP-0733626-B1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GMBH (DE) | 1999-01-13 | — | — | EP | claimed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
| EP-0733626-B1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GMBH (DE) | 1999-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | KMT2A 4594/4885MAPT 3851/4885MEN1 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.